文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

寡转移性前列腺癌盆腔淋巴结复发中挽救性放疗联合激素治疗的2期试验早期毒性(OLIGOPELVIS GETUG P07)

Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07).
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-12-14

BLINDED是一项前瞻性多中心2期试验,评估高剂量挽救性盆腔放疗联合6个月雄激素阻断治疗寡转移性盆腔淋巴结复发前列腺癌的早期毒性。74例患者入组,67例纳入意向性分析,其中一半有既往前列腺照射史。急性及1年毒性可接受,既往前列腺照射患者未显示泌尿或消化道毒性增加。

要点

  • 2级急性泌尿毒性见于9/67例(13.4%),2级1年泌尿毒性见于4/67例(6%)。
  • 3级泌尿毒性见于3例(4.4%)。
  • 2级急性消化道毒性见于10/67例(14.9%),2级1年消化道毒性见于4/67例(6%)。

核心结论

  • BLINDED方案的急性和1年毒性令人满意,即使对有前列腺照射史的患者也是如此。

研究设计与样本

  • BLINDED是一项前瞻性多中心2期试验,研究高剂量挽救性盆腔放疗联合对氟胆碱正电子发射断层扫描阳性盆腔淋巴结加量照射,并联合6个月雄激素阻断。
  • 处方剂量为54 Gy分1.8 Gy次,病理盆腔淋巴结加量至66 Gy分2.2 Gy次。
  • 早期毒性定义为放疗后至1年的毒性。
  • 2014年8月至2016年7月期间在15个法国放射肿瘤科招募74例患者,7例因违反纳入标准在治疗前被排除,意向性分析纳入67例患者。
  • 一半患者既往接受过前列腺照射,中位年龄67.7±6.5岁。

主要发现

  • 2级急性泌尿毒性见于9/67例(13.4%),2级1年泌尿毒性见于4/67例(6%)。
  • 3级泌尿毒性见于3例(4.4%)。
  • 2级急性消化道毒性见于10/67例(14.9%),2级1年消化道毒性见于4/67例(6%)。
  • 既往前列腺床照射的患者未显示泌尿或消化道毒性增加。
  • 欧洲癌症研究与治疗组织问卷评分在1年时未显著恶化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Limited pelvic nodal relapse of prostatic cancer is a paramount challenge for locoregional salvage treatments. Salvage whole pelvis radiation therapy as considered in the BLINDED trial is an attractive option, but there are concerns about its toxicity. This article describes early toxicity with the technique. METHODS AND MATERIALS: BLINDED was a prospective multicenter phase 2 trial investigating high-dose salvage pelvic irradiation with an additional dose to the fluorocholine-based positron emission tomography-positive pelvic lymph nodes, combined with 6-month androgen blockade. The prescribed dose was 54 Gy in 1.8 Gy fractions with up to 66 Gy in 2.2 Gy fractions to the pathologic pelvic lymph nodes. Early toxicity was defined as toxicity until 1 year after radiation therapy. Patients quality of life was assessed using the European Organisation for Research and Treatment of Cancer questionnaires (QLQ-C30 and QLQ-PR25). RESULTS: Seventy-four patients were recruited in 15 French radiation oncology departments between August 2014 and July 2016. Seven were excluded before treatment because of violation of the inclusion criteria. The intention-to-treat analysis therefore included 67 patients. Half had received prior prostatic irradiation. Median age was 67.7 ± 6.5 years. Grade 2 acute urinary toxicity was observed in 9 of 67 patients (13.4%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Three patients (4.4%) had grade 3 urinary toxicity. Grade 2 acute digestive toxicity was observed in 10 of 67 patients (14.9%), and grade 2 1-year toxicity occurred in 4 of 67 patients (6%). Patients with prior prostate bed irradiation did not exhibit increased urinary or digestive toxicity. The European Organisation for Research and Treatment of Cancer questionnaire scores at 1 year did not worsen significantly. CONCLUSIONS: The acute and 1-year toxicity of the BLINDED protocol was satisfactory, even in patients with a history of prostatic irradiation.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Vaugier L, Palpacuer C, Rio E, et al. Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07). Int J Radiat Oncol Biol Phys. 2018. PMID: 30557672. doi:10.1016/j.ijrobp.2018.12.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。